

## **Empower Clinics Unveils Medisure Brand In the United States**

### ***Empower rebrands medical division in the U.S. and accelerates access to the largest hospitals, medical centers and cruiseship opportunities***

#### **VANCOUVER, B.C.: June 20, 2022 – EMPOWER CLINICS INC**

**(CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF)** ("**Empower**" or the "**Company**") an integrated healthcare company offering services in the U.S. and Canada – announced a corporate rebrand of its medical diagnostics laboratory business in the U.S. to Medisure Laboratory, and opens opportunities to the largest healthcare centers in the state of Texas, and leverages its cruiseship connections to the largest ports in the U.S.

The new brand marks an important milestone in the evolution of Empower's presence in the U.S. healthcare market. It represents a fresh and forward-looking approach to the healthcare community, leveraging the Medisure brand as a leading medical device and testing company, to access and support the largest hospital networks with laboratory services in the state of Texas, the cruiseship industry, and film & television productions.

With the company's experience and reputation, and deep connections to major cruise lines, Empower and its accredited laboratory in Texas, have expanded its service offering to key ports in the southern U.S. As a COLA and CLIA accredited laboratory, the company can provide testing and healthcare services to key industries such as film & television, that require testing and healthcare management solutions.

"The Medisure brand is strong, and embodies the energy and growth that we have for our business in the U.S. market," stated Steven McAuley, Chairman and CEO, "Launching Medisure Labs in the U.S. and utilizing our investments just makes sense, it opens new doors, allows us to bring products to market and grow more rapidly. With Medisure Labs, we have a proven brand serving many thousands of patients, that is primed to succeed in the world's largest healthcare market."

Immediate plans for Medisure include researching, applying for and securing additional U.S. Federal Drug and Administration (FDA) certifications to allow for the sale of its medical devices in the U.S. Medisure is also upgrading its quality management systems to expedite the certification process. The company has advanced its offers to the cruiseship industry and to film & television productions.

The new website for Medisure Laboratory is [www.medisurelabs.com](http://www.medisurelabs.com)

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management <https://agoracom.com/ir/EmpowerClinics>

#### **ABOUT EMPOWER:**

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

**ON BEHALF OF THE BOARD OF DIRECTORS:**

Steven McAuley  
Chief Executive Officer

CONTACTS:

Media:

Steven McAuley CEO  
s.mcauley@empowerclinics.com  
604-227-0865

Investors:

Tamara Mason  
  
Business Development &  
Communications  
t.mason@empowerclinics.com  
  
604-359-9107

**DISCLAIMER FOR FORWARD-LOOKING STATEMENTS**

*This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding: the Company's plans for Medisure Labs, the timing of updates or the nature of the changes. Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Company may be unable to enter into definitive agreements, or close transactions with respect to, proposed future clinic openings; that due diligence with respect to anticipated clinic openings and acquisitions may not be satisfactory to the Company; risks related to delays in permitting or construction; risks related to supply chains and access to labour; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for new clinics; general business, economic, competitive, political and social uncertainties; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur on the terms or in the time expected, or at all, or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.*